Recruiting
CPVT

CRD-4730 for Catecholaminergic Polymorphic Ventricular Tachycardia

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

CRD-4730

+ Placebo
Drug
Who is being recruted

Arrhythmias, Cardiac
+6

+ Cardiovascular Diseases
+ Heart Diseases
From 18 to 99 Years
+16 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-Controlled
Phase 2
Interventional
Study Start: December 2025
See protocol details

Summary

Principal SponsorCardurion Pharmaceuticals, Inc.
Study ContactJason Homsy, MD, Ph.D.
Last updated: December 13, 2025
Sourced from a government-validated database.Claim as a partner
Study start date: December 1, 2025Actual date on which the first participant was enrolled.

This study is focused on evaluating a new medication, CRD-4730, for individuals with a heart condition called Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). CPVT can cause irregular heartbeats, which can be dangerous. The study aims to assess how safe and well-tolerated CRD-4730 is, as well as how it behaves in the body and how it affects the heart condition. The research is important because finding effective treatments for CPVT can help prevent life-threatening heart rhythm issues in those affected. Participants in the study will follow a structured plan where they will receive two different doses of CRD-4730 and a placebo at different times. The study is conducted in a way that neither the participants nor the researchers know who is receiving the actual medication or the placebo, ensuring unbiased results. This approach helps determine the safety and effectiveness of CRD-4730 by comparing its impact on the body to that of the placebo. The main focus will be on understanding the drug's safety and how it influences the heart condition.

Official TitleA Phase 2, Double-Blind, Repeat-Dose, Placebo-Controlled Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CRD-4730 In Participants With Catecholaminergic Polymorphic Ventricular Tachycardia 
NCT06658899
Principal SponsorCardurion Pharmaceuticals, Inc.
Study ContactJason Homsy, MD, Ph.D.
Last updated: December 13, 2025
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details
12 patients to be enrolledTotal number of participants that the clinical trial aims to recruit.
Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

How participants are assigned to different groups/arms
In this clinical study, participants are placed into groups randomly, like flipping a coin. This ensures that the study is fair and unbiased, making the results more reliable. By assigning participants by chance, researchers can better compare treatments without external influences.

Other Ways to Assign Participants
Non-randomized allocation: Participants are assigned based on specific factors, such as their medical condition or a doctor's decision.
None (Single-arm trial): If the study has only one group, all participants receive the same treatment, and no allocation is needed.

How treatments are given to participants
Participants receive different treatments one after the other, switching from one to another during the study. This helps researchers understand how individuals respond to multiple treatments.

Other Ways to Assign Treatments
Single-group assignment: Everyone gets the same treatment.
Parallel assignment: Participants are split into separate groups, each receiving a different treatment.
Factorial assignment: Participants receive different combinations of treatments.
Sequential assignment: Participants receive treatments one after another in a specific order, possibly based on individual responses.
Other assignment: Treatment assignment does not follow a standard or predefined design.

How the effectiveness of the treatment is controlled
In a placebo-controlled study, some participants receive the experimental treatment, while others receive an inert substance (placebo) to compare outcomes. This method helps to isolate the effect of the treatment from the psychological effects of receiving any treatment at all.

Other Options
Non-placebo-controlled: No placebo is used. All participants receive the actual treatment or alternative interventions (often the Standard of Care), and comparisons are made between these treatments.

How the interventions assigned to participants is kept confidential
Participants, researchers, outcome assessors, and care providers do not know which treatment is being given. This is the most complete way to prevent bias and keep the study as neutral as possible.

Other Ways to Mask Information
Open-label: Everyone knows which treatment is being given.
Single-blind: Participants do not know which treatment they are receiving, but researchers do.
Double-blind: Neither participants nor researchers know which treatment is given.
Triple-blind: Participants, researchers, and outcome assessors do not know which treatment is given.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria
Any sexBiological sex of participants that are eligible to enroll.
From 18 to 99 YearsRange of ages for which participants are eligible to join.
Healthy volunteers not allowedIf individuals who are healthy and do not have the condition being studied can participate.
Conditions
Pathology
Arrhythmias, Cardiac
Cardiovascular Diseases
Heart Diseases
Pathologic Processes
Pathological Conditions, Signs and Symptoms
Tachycardia
Tachycardia, Ventricular
Cardiac Conduction System Disease
Polymorphic Catecholaminergic Ventricular Tachycardia
Criteria
5 inclusion criteria required to participate
The participant can perform an EST during which frequent premature ventricular contractions (PVCs; ≥10 per minute), ventricular bigeminy, or higher-grade VA (equivalent to a VA score ≥2) are identified by the Investigator.
The participant is male or female, ≥18 years of age and of legal adult age in accordance with local requirements.
The participant has been on a stable dose of at least 1 antiarrhythmic medication (including beta blockers but not amiodarone) for 4 weeks prior to Screening, unless the participant has been unable to tolerate antiarrhythmic therapy previously.
The participant has a confirmed CPVT diagnosis, based on genetic screening for a pathogenic ryanodine receptor (RYR2) mutation and a clinical phenotype consistent with CPVT at Screening. Previous CPVT genetic testing documented in medical history is acceptable if confirmed by the Investigator and documented in the study source records.

Show More Criteria

11 exclusion criteria prevent from participating
The participant has acute or chronic hepatitis B (HBV; defined as hepatitis B surface antigen \[HBsAg\] reactive), acute or chronic hepatitis C virus (HCV; defined as detection of HCV antibody and RNA \[qualitative\]), or human immunodeficiency virus (HIV) infection.
The participant has abnormal blood pressure, defined as supine symptomatic hypotension, systolic blood pressure \>150 mm Hg or diastolic blood pressure \>90 mm Hg, or symptomatic bradycardia or a heart rate \>100 bpm at Screening and/or on Day 1. Blood pressure and pulse should be measured after the participant has been in the seated position after 5 minutes of rest.
The participant has taken any antiarrhythmic drug in addition to their stable, chronic regimen unless it has been at least 5 half-lives since administration at the time of Screening.
The participant has an anticipated change in exercise regimen or new exercise program during the course of the study.

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives
3 intervention groups 

are designated in this study

33.333% chance 

of being blinded to the placebo group

Treatment Groups
Group I
Experimental
CRD-4730 Dose 1 Tablet

Oral CRD-4730 in tablet form
Group II
Experimental
CRD 4730 Dose 2 Tablet

Oral CRD-4730 in tablet form
Group III
Placebo
Placebo tablet to match CRD-4730

Placebo to match CRD-4730 in tablet form
Study Objectives
Primary Objectives

The number and severity of treatment-emergent adverse events (TEAEs) related to study drug treatment
Secondary Objectives

Change in VA score during EST from baseline to Day 15, from baseline to Day 44, and from baseline to Day 73

Plasma concentrations of CRD-4730 over time for each treatment period

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has 3 locations
Recruiting
Cardurion Investigative SiteSan Francisco, United StatesSee the location
Recruiting
Cardurion Investigative SiteHouston, United States
Recruiting
Cardurion Investigative SiteMadison, United States
Recruiting
3 Study Centers